Smith Hunter C

Chief Financial OfficerRHYTHM PHARMACEUTICALS, INC. (RYTM) · full profile →Form 4 · filed Feb 12, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$709K
Net Open-Market Flow
-$709K
Transactions
12
10 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 12, 2026Sell(S)100$100.10$10K118K
Feb 12, 2026Sell(S)800$98.99$79K119K
Feb 12, 2026Sell(S)400$97.67$39K119K
Feb 12, 2026Sell(S)292$96.26$28K120K
Feb 11, 2026Sell(S)2K$98.37$223K121K
Feb 11, 2026Sell(S)100$100.85$10K120K
Feb 11, 2026Sell(S)400$99.44$40K120K
Feb 10, 2026Sell(S)700$103.68$73K123K
Feb 10, 2026Sell(S)100$104.76$10K123K
Feb 10, 2026Sell(S)2K$102.66$196K124K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 11, 2026Grant(A)25K$025K
Feb 11, 2026Grant(A)38K$038K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-26-014546) within minutes of acceptance. Every field above traces to the original document. Verify it directly: